Please login to the form below

Not currently logged in

GSK partners with Singapore research agency on emerging markets

Will work with A*STAR’s Institute of Chemical and Engineering to research reformulated medicines

Will work with A*STAR's Institute of Chemical and Engineering to research reformulated medicines

GlaxoSmithKline (GSK) is to partner with Singapore's lead government agency for research to develop new formulations of existing medicines specifically for emerging markets.

The UK-based pharma company will work with the Agency for Science, Technology and Research's (A*STAR) Institute of Chemical and Engineering Sciences over the next five years to research reformulated medicines, taking advantage of a growing demand for pharmaceutical products in emerging markets, including China, Brazil, India and Russia.

It expands on an existing relationship between A*STAR and GSK that began in 2003 and includes a 2012 agreement with the Agency's Genome Institute of Singapore (GIS) to research treatments for lung cancer.

The latest deal for evidence-based formulations (EBFs) reinforces Singapore as both GSK's hub for emerging markets and an important base for the pharma industry, as companies look towards growth in nearby countries, including Indonesia, India and Vietnam.

Duncan McKay, VP, emerging markets & Asia Pacific R&D, GSK, said the agreement was part of the company's strategy of “growing a diversified global business”.

He said: “Within GSK's portfolio of off-patent products, EBFs are an important part of our growth strategy, and our hope is that together with the Institute of Chemical and Engineering Sciences, we will create a sustainable, scalable model to meet both specific market conditions and patient requirements.”

Kevin Lai, director of biomedical sciences for Singapore's Economic Development Board, gave the government perspective.

“This is a strong endorsement of Singapore's scientific talent and capabilities,” he said. “It also further reinforces Singapore's offering as the base for companies to generate insights and develop new solutions and market access strategies for the fast growing emerging markets.”

9th April 2013

From: Research



Featured jobs

Subscribe to our email news alerts


Add my company
Complete Medical Communications (CMC)

CMC is a leading global agency dedicated to healthcare communications across the lifecycle. We combine scientific acumen, excellence in delivery...

Latest intelligence

figure 1
The valuable brand
Creating value beyond the pill is both possible and increasingly necessary...
The rise of real-world evidence
Demonstrating efficacy and value requires more than clinical trial data...
Digital health
The untapped potential to transform healthcare...